Clinical trials: Nephrosis, Lipoid
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
- Trial name
- NCT07499700
- Testing
- BAT4406F
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Bio-Thera Solutions
Minimal Change Disease
Therapeutic Effect of Tacrolimus in Combination With Low Dose Corticosteroid in Adult Patient With Minimal Change Nephritic Syndrome
The hypothesis of this study is that tacrolimus reduces the proteinuria in adult patient with minimal change nephritic syndrome.
- Trial name
- MCNS (NCT01084980)
- Testing
- Tacrolimus
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
First Manifestation of Steroid Sensitive Nephrotic Syndrome
Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children
Idiopathic Nephrotic Syndrome is sensitive to steroid in 90% of children. However, most patients relapse and become steroid-dependant, with a long lasting relapsing course.
- Trial name
- NEPHROVIR3 (NCT02818738)
- Testing
- Levamisole Hydrochloride
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1
This is a multicentric retrospective observational cohort study. As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, APOL1 Associated Kidney Disease
- Trial name
- NEPHROL1 (NCT06443034)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change
CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
CHILDNEPH is a pan-Canadian project to observe clinical care for children with nephrotic syndrome. Previous studies have indicated that there is wide practice variation in how health care providers treat this remitting and…
- Conditions
- Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome，Idiopathic
- Trial name
- CHILDNEPH (NCT03786263)
- Where
- 12 sites in Canada
- Volunteers
- 400 people
- Sponsor
- University of Calgary
Minimal Change Disease (MCD), IgA Nephropathy (IgAN)
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN.
- Conditions
- Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07614477
- Testing
- EVER001
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Membranous Nephropathy, Minimal Change Disease (MCD)
Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome
Immunophenotyping profiling of patients with primary MN, primary FSGS and MCD. Evaluation of these immune cell subsets as possible biomarkers to track response to treatment or disease relapse.
- Conditions
- Membranous Nephropathy, Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07702981
- Testing
- Rituximab (MABTHERA® or RITUXAN®)., Corticosteroids (CS)
- Where
- Greece
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ioannina
Glomerular Disease
Vitamin D Supplementation in Glomerular Disease
This multi-site, pilot study will assess vitamin D supplementation in children and young adults with Glomerular Disease. .
- Trial name
- NCT01835639
- Testing
- Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Glomerular Disease, Minimal Change Disease
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis…
- Conditions
- Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy
- Trial name
- KORNERSTONE (NCT03929887)
- Testing
- Kidney Biopsy
- Where
- 6 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
Idiopathic Nephrotic Syndrome
Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome
The purpose of this study is to determine whether 7-valent pneumococcal conjugate vaccine safely induces immune responses and immunological memory in children with idiopathic nephrotic syndrome in remission.
- Trial name
- NCT01346007
- Testing
- 7-valent pneumococcal conjugate vaccine
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome
To confirm the efficacy and safety of rituximab (genetical recombination) intravenously administered to idiopathic membranous nephropathy with nephrotic syndrome.
- Trial name
- PRIME (NCT05914155)
- Testing
- Rituximab (genetical recombination)
- Where
- 18 sites in Japan
- Volunteers
- 88 people
- Sponsor
- Shoichi Maruyama MD PhD
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Healthy Volunteers
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
The goal of this research study is to learn more about the pancreas. The investigators want to use Magnetic Resonance Cholangiopancreatography (MRCP) to learn more about the size of a normal pancreas.
- Trial name
- NCT02869893
- Testing
- Secretin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nephrotic Syndrome，Idiopathic
Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
This is a multicenter, open-label, single-arm Phase II clinical trial designed to evaluate the safety, efficacy, and immunological effects of obinutuzumab in adult patients with multi-relapsing, rituximab-dependent…
- Trial name
- OASIS (NCT07233330)
- Testing
- Obinutuzumab
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Nephrotic Syndrome
INSIGHT (Insight Into Nephrotic Syndrome)
INSIGHT is a longitudinal study of childhood nephrotic syndrome to determine genetic, serologic and environmental factors contributing to nephrotic syndrome and disease progression.
- Trial name
- INSIGHT (NCT01605266)
- Where
- 4 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- The Hospital for Sick Children
Idiopathic Nephrotic Syndrome, Minimal Change Disease
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
This will be an open-label, randomized controlled trial which compares continued treatment with high dose prednisone (standard therapy) to treatment with rituximab in patients with minimal change disease or focal segmental…
- Conditions
- Idiopathic Nephrotic Syndrome, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- NCT03298698
- Testing
- Rituximab, Prednisone
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center